The plant, which will see an investment of approximately JPY4.6bn ($48.9m), will consist of four floors and occupy a total area of 4106m² space for each floor.
The HA5 plant is expected to completed by second quarter 2014, and will commences its operations in 2016.
The facility will produce biopharmaceutical injectable drugs, which are currently manufactured at its Fuji plant as well as at the Takasaki plant, and will be marketed in 2017.
Kyowa Hakko Kirin claims that the new HA5 Plant is designed for efficient manufacture of multiple products and will comply with the Good Manufacturing Practices (GMP) for European, US, and Japanese drug products.